SCHEMBL25494284

SCHEMBL25494284

Cc1cc(NC(=O)C(C)(C)C)ccc1C(C)C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.59
▸ L3MBTL1 Q9Y468 1/20 0.56
▸ MAPT P10636 3/20 0.50
▸ ALDH1A1 P00352 3/20 0.50
▸ NPSR1 Q6W5P4 2/20 0.50
▸ KDM4E B2RXH2 2/20 0.50
▸ LCK P06239 1/20 0.50
▸ CTSL P07711 1/20 0.50
▸ PTPRC P08575 1/20 0.50
▸ PTPN2 P17706 1/20 0.50
▸ PTPN1 P18031 1/20 0.50
▸ CTSS P25774 1/20 0.50
▸ PTPN13 Q12923 1/20 0.50
▸ HSP90AA1 P07900 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ HPGD P15428 1/20 0.48
▸ CNR2 P34972 1/20 0.44
▸ CA12 O43570 1/20 0.44
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22399078 0.87 GAA (0.68) GAAL3MBTL1MAPTALDH1A1NPSR1
SCHEMBL25494277 0.84 GAA (0.64) GAAL3MBTL1MAPTALDH1A1NPSR1
SCHEMBL17014550 0.83 GAA (0.58) GAAL3MBTL1MAPTALDH1A1NPSR1
SCHEMBL14199943 0.81 GAA (0.56) GAAL3MBTL1MAPTALDH1A1NPSR1
SCHEMBL25494268 0.81 RAB9A (0.51) GAAMAPTALDH1A1NPSR1KDM4E
SCHEMBL14667344 0.81 L3MBTL1 (0.67) GAAL3MBTL1MAPTALDH1A1NPSR1
SCHEMBL25900637 0.80 KMT2A (0.53) GAAL3MBTL1MAPTALDH1A1NPSR1
SCHEMBL25497034 0.77 TSHR (0.52) GAAMAPTALDH1A1NPSR1KDM4E
SCHEMBL10892785 0.77 ALDH1A1 (0.55) GAAMAPTALDH1A1NPSR1KDM4E
SCHEMBL13652644 0.77 PKM (0.54) GAAMAPTALDH1A1NPSR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279426-A1 MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION LYCIA THERAPEUTICS, INC. 2023-09-07 — — US disclosed
US-20230279426-A1 MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION LYCIA THERAPEUTICS, INC. 2023-09-07 — — US disclosed
US-20230226214-A1 BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION LYCIA THERAPEUTICS, INC. 2023-07-20 — — US disclosed
US-20230158155-A1 Cell Surface Receptor Binding Compounds and Conjugates LYCIA THERAPEUTICS, INC. 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230158155-A1 Cell Surface Receptor Binding Compounds and Conjugates M6PR, ASGR1, IGF2R GAA 83/4885L3MBTL1 765/4885MAPT 3180/4885
US-20230226214-A1 BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION HAVCR2, FCGR3B, FCGR2A GAA 2742/4885L3MBTL1 2521/4885MAPT 3491/4885
US-20230279426-A1 MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION HAVCR2, ASGR1, FCGR3B GAA 1239/4885L3MBTL1 2887/4885MAPT 2544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback